Utility of the PFA-100® for assessing bleeding disorders and monitoring therapy:: a review of analytical variables, benefits and limitations

被引:102
作者
Favaloro, EJ [1 ]
机构
[1] Westmead Hosp, ICPMR, Dept Haematol, Diagnost Haemostasis Lab,WSAHS, Westmead, NSW 2145, Australia
关键词
PFA-100 (R) platelet function; review; von Willebrand factor; von Willebrand's disease; vWD;
D O I
10.1046/j.1365-2516.2001.00486.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The PFA-100(R) (platelet function analyser) is a relatively new tool for the investigation of primary haemostasis. Recent studies have shown its utility in monitoring antiplatelet therapy (including aspirin) and as a screening tool for investigating possible von Willebrand disease (vWD) and various platelet disorders. More recently, the PFA-100(R) has been shown to be of value in monitoring DDAVP therapy in both vWD and platelet disorders. This paper reviews current findings, details the utility of the PFA-100(R) for some of these purposes, as well as reviewing analytical variables that may complicate the interpretation of results. The author highlights the benefits, as well as noting the limitations, of its use. Ultimately, the greatest strengths of the PFA-100(R) are its simplicity in use and excellent sensitivity to particular haemostatic disturbances such as vWD, platelet disorders and platelet-affecting medication. However, because it is thus a 'global' test system, this also creates a significant limitation, as the PFA-100(R) is not specific for, nor predictive of, any particular disorder. However, utilized appropriately, the PFA-100(R) can be considered a worthwhile addition to any haemostasis laboratory involved in the diagnosis or therapeutic-monitoring of bleeding disorders including vWD and platelet-dysfunctions. This review should be of value to both haemostasis scientists and clinical specialists.
引用
收藏
页码:170 / 179
页数:10
相关论文
共 45 条
  • [1] Böck M, 1999, BRIT J HAEMATOL, V106, P898
  • [2] Carcao MD, 1998, BRIT J HAEMATOL, V101, P70
  • [3] Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion
    Cattaneo, M
    Lecchi, A
    Agati, B
    Lombardi, R
    Zighetti, ML
    [J]. THROMBOSIS RESEARCH, 1999, 96 (03) : 213 - 217
  • [4] Cattaneo M, 1999, THROMB HAEMOSTASIS, V82, P35
  • [5] Meloxicam, 15 mg/day, spares platelet function in healthy volunteers
    de Meijer, A
    Vollaard, H
    de Metz, M
    Verbruggen, B
    Thomas, C
    Novakova, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (04) : 425 - 430
  • [6] Dean JA, 2000, THROMB HAEMOSTASIS, V84, P401
  • [7] Low platelet α2β1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system
    Di Paola, J
    Federici, AB
    Mannucci, PM
    Canciani, FT
    Kritzik, M
    Kunicki, TJ
    Nugent, D
    [J]. BLOOD, 1999, 93 (11) : 3578 - 3582
  • [8] Escolar G, 1999, HAEMATOLOGICA, V84, P614
  • [9] Facey DA, 2000, AM J HEMATOL, V63, P197, DOI 10.1002/(SICI)1096-8652(200004)63:4<197::AID-AJH6>3.0.CO
  • [10] 2-2